Inhibition of TGFβ1 activation prevents radiation-induced lung fibrosis

Abstract

• Activated TGFβ1 has a superior capacity in predicting radiation pneumonitis (RP) risk and plays a vital role in the development of radiation-induced pulmonary fibrosis (RIPF).

• Conditional knock out Itgav in myofibroblasts prevented mice from developing RIPF.

• Cilengitide alleviated the development of RIPF by inhibiting αv integrinmediated TGFβ1 activation and may be used in targeted approaches for preventing RIPF.

Keywords

cilengitide / radiation-induced pulmonary fibrosis / transforming growth factor beta 1 / αv integrin

References

[1] HananiaAN, Mainwaring W, GhebreYT, HananiaNA, LudwigM. Radiation-induced lung injury: assessment and management. Chest. 2019;156(1):150-162.

[2] JinH, YooY, KimY, KimY, ChoJ, LeeYS. Radiation-induced lung fibrosis: preclinical animal models and therapeutic strategies. Cancers (Basel). 2020;12(6):1561.

[3] FrangogiannisN. Transforming growth factor-β in tissue fibrosis. J Exp Med. 2020;217(3):e20190103.

[4] YuanX, LiaoZ, LiuZ, et al. Single nucleotide polymorphism at rs1982073: T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiotherapy. J Clin Oncol. 2009;27(20):3370-3378.

[5] BudiEH, SchaubJR, DecarisM, Turner S, DerynckR. TGF-β as a driver of fibrosis: physiological roles and therapeutic opportunities. J Pathol. 2021;254(4):358-373.

[6] LodygaM, HinzB. TGFβ1 - a truly transforming growth factor in fibrosis and immunity. Semin Cell Dev Biol. 2020;101:123-139.

[7] GyörfiAH, MateiAE, DistlerJHW. Targeting TGF-β signalling for the treatment of fibrosis. Matrix Biol. 2018;68–69:8-27.

[8] KimDY, LeeSH, FuY, et al. Del-1, an endogenous inhibitor of TGF-β activation, attenuates fibrosis. Front Immunol. 2020;11:68.

[9] NoskovicovaN, Schuster R, van PuttenS, et al. Suppression of the fibrotic encapsulation of silicone implants by inhibiting the mechanical activation of pro-fibrotic TGF-β. Nat Biomed Eng. 2021;5(12):1437-1456.

[10] SchnittertJ, BansalR, StormG, Prakash J. Integrins in wound healing, fibrosis and tumor stroma: high potential targets for therapeutics and drug delivery. Adv Drug Deliv Rev. 2018;129:37-53.

[11] ReedNI, JoH, ChenC, et al. The alphavbeta1 integrin plays a critical in vivo role in tissue fibrosis. Sci Transl Med. 2015;7(288):288ra79.

[12] PuthawalaK, Hadjiangelis N, JacobySC, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 2008;177(1):82-90.

[13] HendersonNC, ArnoldTD, KatamuraY, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013;19(12):1617-1624.

[14] MurrayIR, Gonzalez ZN, BailyJ, et al. Alphav integrins on mesenchymal cells regulate skeletal and cardiac muscle fibrosis. Nat Commun. 2017;8(1):1118.

[15] WipffPJ, RifkinDB, MeisterJJ, Hinz B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol. 2007;179(6):1311-1323.

[16] ChandranRR, XieY, Gallardo-VaraE, et al. Distinct roles of KLF4 in mesenchymal cell subtypes during lung fibrogenesis. Nat Commun. 2021;12(1):7179.

[17] QinW, LiuB, YiM, et al. Antifibrotic agent pirfenidone protects against development of radiation-induced pulmonary fibrosis in a murine model. Radiat Res. 2018;190(4):396-403.

[18] YiM, LiuB, TangY, Li F, QinW, YuanX. Irradiated human umbilical vein endothelial cells undergo endothelial-mesenchymal transition via the snail/mir-199a-5p axis to promote the differentiation of fibroblasts into myofibroblasts. Biomed Res Int. 2018;2018:4135806.

[19] HarveyT, Flamenco S, FanCM. A Tppp3⁺Pdgfra⁺ tendon stem cell population contributes to regeneration and reveals a shared role for PDGF signalling in regeneration and fibrosis. Nat Cell Biol. 2019;21(12):1490-1503.

[20] KramannR, Schneider RK, DiRoccoDP, et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 2015;16(1):51-66.

[21] LiC, FlynnRS, GriderJR, et al. Increased activation of latent TGFβ1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide. Inflamm Bowel Dis. 2013;19(13):2829-2839.

[22] PatsenkerE, PopovY, WiesnerM, Goodman SL, SchuppanD. Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. J Hepatol. 2007;46(5):878-887.

[23] JarzebskaN, Karetnikova ES, MarkovAG, KasperM, Rodionov RN, SpiethPM. Scarred lung: an update on radiation-induced pulmonary fibrosis. Front Med (Lausanne). 2021;7:585756.

[24] AroraA, BhuriaV, SinghS, et al. Amifostine analog, DRDE-30, alleviates radiation induced lung damage by attenuating inflammation and fibrosis. Life Sci. 2022;298:120518.

[25] KäsmannL, Dietrich A, Staab-WeijnitzCA, et al. Radiation-induced lung toxicity—cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiat Oncol. 2020;15(1):214.

[26] ChenZ, WuZ, NingW. Advances in molecular mechanisms and treatment of radiation-induced pulmonary fibrosis. Transl Oncol. 2019;12(1):162-169.

[27] BagnatoGL, IrreraN, PizzinoG, et al. Dual alphavbeta3 and alphavbeta5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis. Clin Sci (Lond). 2018;132(2):231-242.

[28] BouvetM, ClaudeO, RouxM, et al. Anti-integrin αv therapy improves cardiac fibrosis after myocardial infarction by blunting cardiac PW1⁺ stromal cells. Sci Rep. 2020;10(1):11404.

[29] PatsenkerE, PopovY, StickelF, et al. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology. 2009;50(5):1501-1511.

[30] VansteenkisteJ, Barlesi F, WallerCF, et al. Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Ann Oncol. 2015;26(8):1734-1740.

[31] NaborsLB, FinkKL, MikkelsenT, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015;17(5):708-717.

[32] HaddadT, QinR, LupuR, et al. A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017;79(6):1221-1227.

[33] MassabeauC, Khalifa J, FilleronT, et al. Continuous infusion of cilengitide plus chemoradiotherapy for patients with stage III non-small cell lung cancer: a phase I study. Clin Lung Cancer. 2018;19(3):e277-e285.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.